Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + midostaurin maintenance after allogeneic stem cell transplantation for FLT3-ITD AML
NL-OMON48580Phase 1Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of panobinostat and midostaurin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by HOVON. Primary endpoint: Dose-limiting toxicity during first cycle. Started Aug 2018; status: active, not recruiting.
02
Drugs
panobinostatmidostaurin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON48580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48580.